HER2-mutant Non-Small Cell Lung Cancer Pipeline Drugs 2024 | Dizal Pharmaceuticals, Puma Biotechnology, AstraZeneca, Jiangsu Hengrui Medicine, Spectrum Pharmaceuticals Inc., and others.

DelveInsight's, "HER2-mutant Non-Small Cell Lung Cancer Pipeline Insight 2024" report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in HER2-mutant Non-Small Cell Lung Cancer pipeline landscape. It covers the HER2-mutant Non-Small Cell Lung Cancer pipeline drug profiles, including clinical and nonclinical stage products. It also covers the HER2-mutant Non-Small Cell Lung Cancer therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Explore our latest breakthroughs in HER2-mutant Non-Small Cell Lung Cancer Research. Learn more about our innovative pipeline today! @ HER2-mutant Non-Small Cell Lung Cancer Pipeline Outlook- https://www.delveinsight.com/sample-request/her2-mutant-non-small-cell-lung-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Key Takeaways from the HER2-mutant Non-Small Cell Lung Cancer Pipeline Report
• May 2024:- M.D. Anderson Cancer Center- This phase II trial studies how well poziotinib works in treating patients with non-small lung cancer with an EGFR or HER2 exon 20 mutation that is stage IV or has come back (recurrent). Poziotinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
• April 2024:- AstraZeneca- An Open-label, Single-arm, Phase 2 Study to Evaluate the Efficacy and Safety of Trastuzumab Deruxtecan (T-DXd) for Patients With HER2-mutant Metastatic NSCLC Who Have Disease Progression on or After at Least One-line of Treatment (DESTINY-Lung05). The purpose of this study is to evaluate the efficacy and safety of T-DXd in participants with HER2 mutant metastatic non-squamous NSCLC.
• DelveInsight's HER2-mutant Non-Small Cell Lung Cancer pipeline report depicts a robust space with 5+ active players working to develop 5+ pipeline therapies for HER2-mutant Non-Small Cell Lung Cancer treatment.
• The leading HER2-mutant Non-Small Cell Lung Cancer Companies such as Dizal Pharmaceuticals, Puma Biotechnology, AstraZeneca, Jiangsu Hengrui Medicine, Spectrum Pharmaceuticals Inc., and others.
• Promising HER2-mutant Non-Small Cell Lung Cancer Therapies such as Trastuzumab deruxtecan, Poziotinib, and others.

Stay informed about the cutting-edge advancements in HER2-mutant Non-Small Cell Lung Cancer Treatments. Download for updates and be a part of the revolution in oncology care @ HER2-mutant Non-Small Cell Lung Cancer Clinical Trials Assessment- https://www.delveinsight.com/sample-request/her2-mutant-non-small-cell-lung-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

HER2-mutant Non-Small Cell Lung Cancer Emerging Drugs Profile
• DZD-9008: Dizal Pharmaceuticals
DZD9008 is a selective, irreversible EGFR inhibitor, which is currently being evaluated for the treatment of both EGFRexon20 insertion mutation-positive NSCLC and HER2-mutated NSCLC. In the open-label, multicenter phase I/II study (NCT03974022), 220 patients with EGFRexon20 insertion mutation-positive or HER2-positive NSCLC were treated with DZD9008 at doses of 50 mg to 400 mg once daily.
• Enhertu: AstraZeneca
Enhertu is a HER2-directed ADC. Designed using Daiichi Sankyo's proprietary DXd ADC technology, Enhertu is the lead ADC in the oncology portfolio of Daiichi Sankyo and the most advanced programme in AstraZeneca's ADC scientific platform. Enhertu consists of a HER2 monoclonal antibody attached to a topoisomerase I inhibitor payload, an exatecan derivative, via a stable tetrapeptide-based cleavable linker. Enhertu (5.4mg/kg) is approved in more than 40 countries for the treatment of adult patients with unresectable or metastatic HER2-positive breast cancer who have received two or more prior anti-HER2-based regimens based on the results from the DESTINY-Breast01 trial. Enhertu (6.4mg/kg) is approved in several countries for the treatment of adult patients with locally advanced or metastatic HER2-positive gastric or gastro esophageal junction (GEJ) adenocarcinoma who have received a prior trastuzumab-based regimen based on the results from the DESTINY-Gastric01 trial.
• Pyrotinib: Jiangsu Hengrui Medicine
Pyrotinib is a novel irreversible and selective EGFR/HER2 tyrosine kinase inhibitor developed by Hengrui. In 2018, pyrotinib was approved in China in combination with capecitabine for the treatment of relapsed or metastatic HER2-positive breast cancer. Currently, two Phase III studies are ongoing to evaluate pyrotinib as 1st-line treatment (NCT03863223) and extended adjuvant treatment (NCT03980054), respectively in HER2-positive breast cancer patients. In addition to breast cancer, pyrotinib demonstrated superior clinical benefits in advanced non-small cell lung cancer (NSCLC) with HER2 exon 20 mutation in a Phase II study. A global Phase III study (NCT04447118) is ongoing to investigate pyrotinib in patients with advanced non-squamous NSCLC with HER2 exon 20 mutation who previously failed platinum-based chemotherapy.

Learn more about HER2-mutant Non-Small Cell Lung Cancer Drugs opportunities in our groundbreaking HER2-mutant Non-Small Cell Lung Cancer Research and development projects @ HER2-mutant Non-Small Cell Lung Cancer Unmet Needs- https://www.delveinsight.com/sample-request/her2-mutant-non-small-cell-lung-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

HER2-mutant Non-Small Cell Lung Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration.
• Intra-articular
• Intraocular
• Intrathecal
• Intravenous
• Ophthalmic
• Oral
• Parenteral
• Subcutaneous
• Topical
• Transdermal

HER2-mutant Non-Small Cell Lung Cancer Products have been categorized under various Molecule types such as
• Oligonucleotide
• Peptide
• Small molecule

Discover the latest advancements in HER2-mutant Non-Small Cell Lung Cancer Treatment by visiting our website. Stay informed about how we're transforming the future of Oncology @ HER2-mutant Non-Small Cell Lung Cancer Market Drivers and Barriers, and Future Perspectives- https://www.delveinsight.com/sample-request/her2-mutant-non-small-cell-lung-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Scope of the HER2-mutant Non-Small Cell Lung Cancer Pipeline Report
• Coverage- Global
• HER2-mutant Non-Small Cell Lung Cancer Companies- Dizal Pharmaceuticals, Puma Biotechnology, AstraZeneca, Jiangsu Hengrui Medicine, Spectrum Pharmaceuticals Inc., and others.
• HER2-mutant Non-Small Cell Lung Cancer Therapies- Trastuzumab deruxtecan, Poziotinib, and others.
• HER2-mutant Non-Small Cell Lung Cancer Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• HER2-mutant Non-Small Cell Lung Cancer Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

For a detailed overview of our latest research findings and future plans, read the full details of HER2-mutant Non-Small Cell Lung Cancer Pipeline on our website @ HER2-mutant Non-Small Cell Lung Cancer Drugs and Companies- https://www.delveinsight.com/sample-request/her2-mutant-non-small-cell-lung-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Table of Content
1. Introduction
2. Executive Summary
3. HER2-mutant Non-Small Cell Lung Cancer: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. HER2-mutant Non-Small Cell Lung Cancer- DelveInsight's Analytical Perspective
7. Late Stage Products (Preregistration)
8. Enhertu: AstraZeneca
9. Drug profiles in the detailed report…..
10. Mid Stage Products (Phase II)
11. DZD-9008: Dizal Pharmaceuticals
12. Drug profiles in the detailed report…..
13. Early Stage Products (Phase I)
14. Drug name : Company name
15. Drug profiles in the detailed report…..
16. Preclinical and Discovery Stage Products
17. Drug name : Company name
18. Drug profiles in the detailed report…..
19. Inactive Products
20. HER2-mutant Non-Small Cell Lung Cancer Key Companies
21. HER2-mutant Non-Small Cell Lung Cancer Key Products
22. HER2-mutant Non-Small Cell Lung Cancer- Unmet Needs
23. HER2-mutant Non-Small Cell Lung Cancer- Market Drivers and Barriers
24. HER2-mutant Non-Small Cell Lung Cancer- Future Perspectives and Conclusion
25. HER2-mutant Non-Small Cell Lung Cancer Analyst Views
26. HER2-mutant Non-Small Cell Lung Cancer Key Companies
27. Appendix

About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Contact Us
Yash Bhardwaj
info@delveinsight.com

This release was published on openPR.